





RealRate

PHARMACEUTICAL 2023

Corbus Pharmaceuticals Holdings Inc. Rank 272 of 446



The relative strengths and weaknesses of Corbus Pharmaceuticals Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corbus Pharmaceuticals Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Corbus Pharmaceuticals Holdings Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 14% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	60,181
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,640
Liabilities, Non-Current	20,682
Other Assets	4,517
Other Compr. Net Income	-64
Other Expenses	5,000
Other Liabilities	0
Other Net Income	-2,511
Other Revenues	0
Property and Equipment	1,614
Research and Development	16,137
Selling, General and Administrative Expense	18,699

Output Variable	Value in 1000 USD
Assets	66,312
Liabilities	33,322
Expenses	39,835
Revenues	0
Stockholders Equity	32,990
Net Income	-42,347
Comprehensive Net Income	-42,379
Economic Capital Ratio	29%